Sysmex Buys OGT To Add Cytogenics Capability
Oxford Gene Technology announced May 31 that it will become a wholly owned subsidiary of Sysmex, the Japanese in vitro diagnostics company that will gain entry into the cytogenetics market with OGT's fluorescence in situ hybridization and array comparative genomic hybridization products.
You may also be interested in...
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.